BioVenture VoiCes with Chris Garabedian Episode 17: Norwest Venture Partners' Tiba Aynechi
Apr 21, 2025
Tiba Aynechi, a General Partner at Norwest Venture Partners with over 20 years in biotech, shares her fascinating career journey entirely centered in the Bay Area. She reflects on her early days in business development, the thrill of the genomics revolution, and her transition from academia to venture capital without formal training. Topics include innovative biotech investments like iRhythm's ECG technology, the impact of extended remote health monitoring on patient care, and the vital relationship between data quality and funding success in the industry.
AI Snips
Chapters
Transcript
Episode notes
From Biophysics to Venture Spark
- Tiba started as a scientist with a PhD in biophysics focused on computational biology, sparking interest in applying science broadly.
- An IPO class at UCSF was the pivotal moment that led her towards a venture career instead of academia or medical school.
Banking Internship Bridged to Venture
- Tiba interned and then worked full-time at Burrill, gaining exposure to venture and banking transactions.
- This banking experience uniquely equipped her for biotech investing, especially in deal diligence and licensing.
Novo Ventures' Unique Structure
- Novo Ventures is a single LP fund investing foundation money, not Novo Nordisk's corporate funds.
- This structure enables long-term investment patience distinct from typical corporate venture funds.